Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708949 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
A Phase 2 study of Renal Cell Carcinoma, Clear Cell, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT06708949 is a Phase 2 study of Renal Cell Carcinoma, Clear Cell that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT06708949, a Phase 2 study of Renal Cell Carcinoma, Clear Cell, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W) intravenous (IV) versus a doublet arm treating with nivolumab 480 mg Q3W and ipilimumab 1mg/kg Q3W IV in first-line advanced RCC.
Conditions Studied
Interventions
- DRUG Ipilimumab
- DRUG Drugs Nivolumab
- DRUG BMS-986213 (Relatlimab-Nivolumab FDC)
Study Locations (5)
Texas
- University of Texas Southwestern Medical Center - Dallas
- The University of Texas M. D. Anderson Cancer Center - Houston
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- Duke University Medical Center - Durham
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2028-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06708949
The ClinicalTrials.gov registry entry for NCT06708949 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma, Clear Cell appearing as the primary indexed condition, and to 3 interventions - of which Ipilimumab is the first listed.
NCT06708949 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06708949 about?
NCT06708949 is a clinical study titled "A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)". This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W) intravenous (IV) versus a doublet arm treating with nivolumab 480 mg Q3W and i...
What is the current status of trial NCT06708949?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2025-03-20. Estimated completion is 2028-12-15.
What conditions does trial NCT06708949 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Clear Cell.
What interventions are being tested in trial NCT06708949?
The interventions under investigation include: Ipilimumab (DRUG), Drugs Nivolumab (DRUG), BMS-986213 (Relatlimab-Nivolumab FDC) (DRUG).
Who is sponsoring clinical trial NCT06708949?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06708949 being conducted?
This trial has 5 study locations across Massachusetts, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.